Propanc Biopharma Approves 1-for-2 to 1-for-10 Reverse Stock Split

• Propanc Biopharma's board and majority stockholder authorized a reverse stock split on October 6, 2026, through board approval and shareholder written consent.
• The board will select a reverse split ratio between 1-for-2 and 1-for-10 to support financing and capital-raising capacity.
• Outstanding common shares would fall from approximately 10,331,116 to between 1,033,112 and 5,165,558, depending on the selected ratio.
• The split will take effect when Nasdaq processes and approves the action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047806), on October 21, 2026, and is solely responsible for the information contained therein.